SI2719708T1 - Material in postopki za zdravljenje ali preprečevanje bolezni, povezanih s HER-3 - Google Patents
Material in postopki za zdravljenje ali preprečevanje bolezni, povezanih s HER-3 Download PDFInfo
- Publication number
- SI2719708T1 SI2719708T1 SI201031627T SI201031627T SI2719708T1 SI 2719708 T1 SI2719708 T1 SI 2719708T1 SI 201031627 T SI201031627 T SI 201031627T SI 201031627 T SI201031627 T SI 201031627T SI 2719708 T1 SI2719708 T1 SI 2719708T1
- Authority
- SI
- Slovenia
- Prior art keywords
- agent
- seq
- antibody
- use according
- cancer
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 6
- 201000010099 disease Diseases 0.000 title claims abstract 5
- 239000000463 material Substances 0.000 title claims abstract 3
- 238000000034 method Methods 0.000 title claims abstract 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract 34
- 102000025171 antigen binding proteins Human genes 0.000 claims abstract 5
- 108091000831 antigen binding proteins Proteins 0.000 claims abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 230000003463 hyperproliferative effect Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 206010073324 Keratinising squamous cell carcinoma of nasopharynx Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- -1 anthracycline Chemical compound 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 208000028133 nasopharyngeal squamous cell carcinoma Diseases 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (11)
- Material in postopki za zdravljenje ali preprečevanje bolezni, povezanih s HER-3 Patentni zahtevki1. Prvo sredstvo in drugo sredstvo za uporabo pri zdravljenju ali preprečevanju hiperproliferativne bolezni, povezane s HER-3, kjer je hiperproliferativna bolezen rak, ki izraža ali prekomerno izraža HER-3, kjer je drugo sredstvo trastuzumab in kjer je prvo sredstvo antigen vezavni protein, ki se veže na HER-3 in obsega: težkoverižno aminokislinsko sekvenco, ki obsega CDRH1, kot je prikazano v SEQ ID NO: 256; CDRH2, kot je prikazano v SEQ ID NO: 282; in CDRH3, kot je prikazano v SEQ ID NO: 315; in lahkoverižno aminokislinsko sekvenco, ki obsega CDRL1, kot je prikazano v SEQ ID NO: 340; CDRL2, kot je prikazano v SEQ ID NO: 344; in CDRL3, kot je prikazano v SEQ ID NO: 387.
- 2. Prvo sredstvo in drugo sredstvo za uporabo po zahtevku 1, kjer je prvo sredstvo antigen vezavni protein, ki se veže na HER-3 in obsega težkoverižno aminokislinsko sekvenco, kot je prikazano v SEQ ID NO: 70, ali/in lahkoverižno aminokislinsko sekvenco, kot je prikazano v SEQ ID NO: 72.
- 3. Prvo sredstvo in drugo sredstvo za uporabo po zahtevku 1, kjer je prvo sredstvo antigen vezavni protein, ki se veže na HER-3 in obsega težkoverižno aminokislinsko sekvenco od SEQ ID NO: 70 in lahkoverižno aminokislinsko sekvenco od SEQ ID NO: 72.
- 4. Prvo sredstvo in drugo sredstvo za uporabo po katerem koli od zahtevkov 3-6, kjer je antigen vezavni protein usmerjen proti ekstracelulami domeni od HER-3 ali zmanjša signalno transdukcijo, posredovano s HER-3, ali zmanjša fosforilacijo HER- 3 ali zmanjša celično proliferacijo ali zmanjša celično migracijo ali/in poveča zniževanje (downregulation) HER-3.
- 5. Prvo sredstvo in drugo sredstvo za uporabo po katerem koli od prejšnjih zahtevkov, kjer je antigen vezavni protein, ki se veže na HER-3, protitelo, zlasti monoklonsko protitelo, poliklonsko protitelo, rekombinantno protitelo, humanizirano protitelo, humano protitelo, himemo protitelo, multispecifično protitelo ali protitelesni fragment le-teh, zlasti fragment Fab, fragment Fab’, fragment F(ab’)2, fragment Fv, diatelo ali enoverižna protitelesna molekula, zlasti protitelo tipa IgGl, IgG2, IgG3 ali IgG4.
- 6. Prvo sredstvo in drugo sredstvo za uporabo po zahtevku 1, kjer je prvo sredstvo pripojeno na efektorsko skupino, zlasti na radioizotop ali radionuklid, toksin ali terapevtsko ali kemoterapevtsko skupino, kjer je terapevtska ali kemoterapevtska skupina prednostno kaliheamicin, avristatinPE, geldanamicin, majtanzin in derivati le-teh.
- 7. Prvo sredstvo in drugo sredstvo za uporabo po zahtevku 1, kjer zdravljenje ali preprečevanje obsega dajanje nadaljnjega terapevtskega sredstva in/ali radiacijske terapije, kjer je nadaljnje terapevtsko sredstvo prednostno antineoplastično sredstvo ali protitumorsko protitelo ali kemoterapevtsko sredstvo, kjer je kemoterapevtsko sredstvo prednostno izbrano iz skupine, ki jo sestavljajo kapecitabin, antraciklin, doksorubicin, ciklofosfamid, paklitaksel, docetaksel, cisplatin, gemcitabin in karboplatin.
- 8. Prvo sredstvo in drugo sredstvo za uporabo po zahtevku 1, kjer sta prvo sredstvo in drugo sredstvo za dajanje z intravenoznim, subkutanim, intramuskulamim ali peroralnim dajanjem.
- 9. Prvo sredstvo in drugo sredstvo za uporabo po zahtevku 1, kjer je hiperproliferativna bolezen izbrana iz skupine, ki jo sestavljajo rak dojke, rak jajčnika, rak prostate, rak kolona, ledvični rak, pljučni rak, pankreasni rak, epidermoidni karcinom, fibrosarkom, melanom, nazofaringealni karcinom in karcinom skvamoznih celic.
- 10. Prvo sredstvo in drugo sredstvo za uporabo po zahtevku 1, kjer zdravljenje ali preprečevanje obsega dajanje prvega sredstva ali drugega sredstva v odmerku od približno 1 mg do približno 20 mg na kilogram telesne mase vsaj enkrat vsakih 6 tednov.
- 11. Prvo sredstvo in drugo sredstvo za uporabo po zahtevku 1, kjer zdravljenje ali preprečevanje po dajanju posamezniku nadalje obsega nadzorovanje terapevtskega izida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26114909P | 2009-11-13 | 2009-11-13 | |
EP13189092.3A EP2719708B1 (en) | 2009-11-13 | 2010-11-12 | Material and methods for treating or preventing HER-3 associated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2719708T1 true SI2719708T1 (sl) | 2018-03-30 |
Family
ID=43618172
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201031627T SI2719708T1 (sl) | 2009-11-13 | 2010-11-12 | Material in postopki za zdravljenje ali preprečevanje bolezni, povezanih s HER-3 |
SI201032011T SI3351558T1 (sl) | 2009-11-13 | 2010-11-12 | Material in postopki za zdravljenje ali preprečevanje bolezni, povezanih s HER-3 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201032011T SI3351558T1 (sl) | 2009-11-13 | 2010-11-12 | Material in postopki za zdravljenje ali preprečevanje bolezni, povezanih s HER-3 |
Country Status (25)
Country | Link |
---|---|
US (4) | US9101760B2 (sl) |
EP (5) | EP2719708B1 (sl) |
JP (5) | JP5931736B2 (sl) |
KR (1) | KR101806323B1 (sl) |
CN (2) | CN102812045B (sl) |
AR (1) | AR080564A1 (sl) |
AU (1) | AU2010319483B2 (sl) |
BR (1) | BR112012012160B1 (sl) |
CA (1) | CA2780935C (sl) |
CY (2) | CY1119751T1 (sl) |
DK (2) | DK2719708T3 (sl) |
ES (3) | ES2647466T3 (sl) |
HK (1) | HK1207651A1 (sl) |
HR (2) | HRP20180104T1 (sl) |
HU (2) | HUE035605T2 (sl) |
LT (2) | LT3351558T (sl) |
MX (3) | MX357972B (sl) |
NO (1) | NO2719708T3 (sl) |
PL (2) | PL2719708T3 (sl) |
PT (2) | PT2719708T (sl) |
RS (2) | RS60390B1 (sl) |
SI (2) | SI2719708T1 (sl) |
TW (1) | TWI630916B (sl) |
UY (1) | UY33034A (sl) |
WO (1) | WO2011060206A2 (sl) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101155579B (zh) | 2005-02-03 | 2012-10-31 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
CN103110948A (zh) | 2005-11-04 | 2013-05-22 | 惠氏公司 | mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合 |
AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
US9365634B2 (en) * | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
KR20130088908A (ko) | 2008-06-17 | 2013-08-08 | 와이어쓰 엘엘씨 | Hki-272 및 비노렐빈을 함유하는 항신생물성 조합물 |
CN109464445A (zh) | 2008-08-04 | 2019-03-15 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
JP2012505637A (ja) | 2008-10-15 | 2012-03-08 | アンジオケム,インコーポレーテッド | Glp−1アゴニストのコンジュゲート及びその使用 |
CN104447995A (zh) * | 2009-03-20 | 2015-03-25 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
ES2941894T3 (es) | 2009-04-06 | 2023-05-26 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib contra el cáncer de mama |
ES2535176T3 (es) | 2009-09-28 | 2015-05-06 | Qilu Pharmaceutical Co., Ltd | Derivados de 4-(anilino sustituido)quinazolina como inhibidores de la tirosina quinasa |
ES2691717T3 (es) | 2009-10-30 | 2018-11-28 | Novartis Ag | Bibliotecas universales del dominio de unión del lado inferior de tipo iii de la fibronectina de tipo III |
AU2015201262B2 (en) * | 2009-11-13 | 2017-04-27 | Amgen Inc. | Material and methods for treating or preventing her-3 associated diseases |
SI2516469T1 (sl) | 2009-12-22 | 2016-05-31 | Roche Glycart Ag | Protitelesa proti her3 in uporabe le-teh |
JP6092773B2 (ja) | 2010-07-30 | 2017-03-08 | ノバルティス アーゲー | フィブロネクチンクレードル分子及びそのライブラリ |
ME02637B (me) | 2010-08-20 | 2017-06-20 | Novartis Ag | Antitela za receptor 3 faktora rasta epiderma (her3) |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
CA2816520C (en) | 2010-11-01 | 2017-11-21 | Symphogen A/S | Anti-her3 antibodies and compositions |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
SG11201400150TA (en) | 2011-09-30 | 2014-03-28 | Regeneron Pharma | Anti-erbb3 antibodies and uses thereof |
CN104053670A (zh) | 2011-10-31 | 2014-09-17 | 百时美施贵宝公司 | 具有降低的免疫原性的纤连蛋白结合域 |
BR112014012539B1 (pt) | 2011-11-23 | 2022-12-20 | Medimmune, Llc | Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo |
CN104159924B (zh) * | 2011-12-05 | 2018-03-16 | 诺华股份有限公司 | 表皮生长因子受体3(her3)的抗体 |
MX2014006731A (es) * | 2011-12-05 | 2015-06-04 | Novartis Ag | Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3) dirigidos al dominio iii y al dominio iv del her3. |
EP2817335A1 (en) * | 2012-02-22 | 2014-12-31 | U3 Pharma GmbH | Combination of hb-egf binding protein and egfr inhibitor |
EP2817340B1 (en) * | 2012-02-23 | 2020-12-09 | Daiichi Sankyo Europe GmbH | Her3 inhibitor for modulating radiosensitivity |
JP6325527B2 (ja) * | 2012-05-02 | 2018-05-16 | シムフォゲン・アクティーゼルスカブSymphogen A/S | ヒト化pan−her抗体組成物 |
WO2014026286A1 (en) * | 2012-08-14 | 2014-02-20 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
EP2727943A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Trispecific antibodies against human EGFR, HER2 and HER3 |
US20150259430A1 (en) | 2012-11-05 | 2015-09-17 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
EP2727942A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Bispecific antibodies against human EGFR, HER2, and HER3 |
ES2855169T3 (es) * | 2012-11-12 | 2021-09-23 | Angiochem Inc | Conjugados de polipéptido-anticuerpo derivados de aprotinina |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
WO2015048008A2 (en) | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
CN111228511B (zh) * | 2014-04-10 | 2024-06-18 | 第一三共株式会社 | 抗her3抗体-药物偶联物 |
WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
WO2016038609A1 (en) * | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
WO2016038610A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
CN104861068B (zh) * | 2015-01-23 | 2020-11-17 | 中国人民解放军军事科学院军事医学研究院 | 一种全人源抗her3抗体及其治疗相关疾病的用途 |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
ES2826827T3 (es) | 2015-06-15 | 2021-05-19 | Angiochem Inc | Métodos para el tratamiento de carcinomatosis leptomeníngea |
BR112017027690A2 (pt) | 2015-06-29 | 2018-10-09 | Daiichi Sankyo Co Ltd | método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco |
WO2017102789A1 (en) * | 2015-12-17 | 2017-06-22 | F. Hoffmann-La Roche Ag | Combination therapy of anti-her3 antibodies and anti-her2 antibodies |
CA3033694C (en) * | 2016-09-15 | 2023-06-27 | Universitat Stuttgart | Antigen binding protein against her3 |
EP3552626A4 (en) | 2016-12-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR |
JP6679762B2 (ja) | 2017-01-17 | 2020-04-15 | 第一三共株式会社 | 抗gpr20抗体及び抗gpr20抗体−薬物コンジュゲート |
BR112019015915A2 (pt) * | 2017-02-28 | 2020-04-07 | Daiichi Sankyo Co Ltd | método para o tratamento de câncer de pulmão de células não pequenas resistentes a egfr-tki através da administração do conjugado de anticorpo anti-her3-fármaco |
JP7328151B2 (ja) * | 2017-04-28 | 2023-08-16 | シージェン インコーポレイテッド | Her2陽性がんの処置 |
TW202330036A (zh) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
EP3677589A4 (en) | 2017-08-31 | 2021-04-21 | Daiichi Sankyo Company, Limited | IMPROVED PROCESS FOR PREPARING ANTIBODY-ACTIVE CONJUGATE |
CN117838880A (zh) | 2017-08-31 | 2024-04-09 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
CN117815404A (zh) | 2018-05-18 | 2024-04-05 | 第一三共株式会社 | 抗-muc1抗体-药物缀合物 |
US20210246223A1 (en) * | 2018-06-22 | 2021-08-12 | Crd Pharmaceuticals Inc | ANTI-HER3 Antibody and uses thereof |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
JP2023512214A (ja) | 2020-01-28 | 2023-03-24 | リフレクション メディカル, インコーポレイテッド | 放射性核種および外部ビーム放射線療法の共同最適化 |
WO2023165475A1 (zh) * | 2022-03-03 | 2023-09-07 | 四川科伦博泰生物医药股份有限公司 | Her3结合蛋白及其用途 |
TW202400245A (zh) * | 2022-04-29 | 2024-01-01 | 大陸商四川科倫博泰生物醫藥股份有限公司 | 抗體藥物偶聯物及其製備方法和用途 |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1467383A (en) | 1974-06-12 | 1977-03-16 | Farmaceutici Italia | Daunomycin analogues |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399276A (en) | 1981-01-09 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | 7-Substituted camptothecin derivatives |
US4471052A (en) | 1982-01-18 | 1984-09-11 | Adria Laboratories, Inc. | Biosynthesis of simplified anthracyclines |
JPS58166633A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
JPS58166634A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
JPS62170639A (ja) | 1986-01-22 | 1987-07-27 | 株式会社システムメンテナンス | 防蟻板の取付け工法 |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US4939168A (en) | 1989-08-11 | 1990-07-03 | Harbor Branch Oceanographics Institution, Inc. | Discodermolide compounds, compositions containing same and methods of preparation and use |
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69133557D1 (de) | 1990-08-29 | 2007-03-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
NZ253943A (en) | 1992-06-18 | 1997-01-29 | Genpharm Int | Transfering polynucleotides into eukaryotic cells using co-lipofection complexes of a cationic lipid and the polynucleotide |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
CA2129288C (en) | 1993-08-17 | 2000-05-16 | Jerzy Golik | Phosphonooxymethyl esters of taxane derivatives |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
JPH09506250A (ja) * | 1993-11-23 | 1997-06-24 | ジェネンテク,インコーポレイテッド | Rseと命名される蛋白チロシンキナーゼ |
FR2718135B1 (fr) | 1994-04-05 | 1996-04-26 | Rhone Poulenc Rorer Sa | Procédé de préparation d'hydroxy-7 taxanes. |
FR2721928A1 (fr) | 1994-07-04 | 1996-01-05 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
TW321649B (sl) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
US5837815A (en) * | 1994-12-15 | 1998-11-17 | Sugen, Inc. | PYK2 related polypeptide products |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US6150581A (en) * | 1995-06-07 | 2000-11-21 | United States Surgical Corporation | Chitosan/alginate anti-adhesion barrier |
WO1997007671A1 (fr) | 1995-08-29 | 1997-03-06 | Kirin Beer Kabushiki Kaisha | Animal chimerique et procede de constitution |
US5681847A (en) | 1995-12-05 | 1997-10-28 | Harbor Branch Oceanographic Institution, Inc. | Methods of using discodermolide compounds |
US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
AU727082B2 (en) | 1996-03-27 | 2000-11-30 | Genentech Inc. | ErbB3 antibodies |
US6114595A (en) * | 1996-04-11 | 2000-09-05 | The Procter & Gamble Company | Stretchable, extensible composite topsheet for absorbent articles |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
ES2227729T3 (es) | 1996-12-11 | 2005-04-01 | Sugen, Inc. | Metodos de cribaje para compuestos unidos al polipeptido pyk2. |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
JP4662635B2 (ja) | 1998-11-20 | 2011-03-30 | コーサン バイオサイエンシーズ, インコーポレイテッド | エポチロンおよびエポチロン誘導体を生成するための組換え方法および材料 |
EP1141722A1 (en) | 1998-12-31 | 2001-10-10 | Sugen, Inc. | Pyk2 (raftk) and inflammation |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
SI1189641T1 (sl) | 1999-06-25 | 2009-12-31 | Genentech Inc | Humanizirana protitelesa proti ErbB2 in zdravljenje s protitelesi proti ErbB2 |
US6627196B1 (en) | 1999-08-27 | 2003-09-30 | Genentech, Inc. | Dosages for treatment with anti-ErbB2 antibodies |
FR2817258B1 (fr) * | 2000-11-27 | 2003-01-10 | Atofina | Procede de sulfochloration photochimique d'alcanes gazeux |
IL152420A0 (en) | 2001-02-23 | 2003-05-29 | Novartis Ag | Novel oncolytic adenoviral vectors |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
WO2003047336A2 (en) | 2001-11-30 | 2003-06-12 | Abgenix, Inc. | TRANSGENIC ANIMALS BEARING HUMAN Igμ LIGHT CHAIN GENES |
ATE374944T1 (de) | 2001-12-03 | 2007-10-15 | Abgenix Inc | Identifizierung hochaffiner moleküle durch screening mit begrenzter verdünnung |
EP1495123B1 (en) | 2002-03-26 | 2013-10-30 | Zensun (Shanghai) Science and Technology Limited | Erbb3 based methods and compositions for treating neoplasms |
US7332580B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
EP1540347B1 (en) | 2002-07-25 | 2009-09-09 | Aclara BioSciences, Inc. | Detecting receptor oligomerization |
WO2004050683A2 (en) | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
WO2004092353A2 (en) | 2003-04-01 | 2004-10-28 | Monogram Biosciences, Inc. | Surface receptor complexes as biomarkers |
JP2005024385A (ja) | 2003-07-02 | 2005-01-27 | Matsushita Electric Ind Co Ltd | 感圧センサ |
CA2597958C (en) | 2005-02-18 | 2019-01-15 | Angiochem Inc. | Molecules for transporting a compound across the blood-brain barrier |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
EP1931798A1 (en) * | 2005-10-05 | 2008-06-18 | AstraZeneca UK Limited | Method to predict or monitor the response of a patient to an erbb receptor drug |
AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
WO2008100624A2 (en) * | 2007-02-16 | 2008-08-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
GB0706633D0 (en) * | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
PE20090368A1 (es) * | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
EP2138511A1 (en) * | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
CN103002912A (zh) * | 2009-08-21 | 2013-03-27 | 梅里麦克制药股份有限公司 | 针对ErbB3的胞外结构域的抗体及其用途 |
-
2010
- 2010-11-12 CN CN201080052236.XA patent/CN102812045B/zh active Active
- 2010-11-12 LT LTEP17197711.9T patent/LT3351558T/lt unknown
- 2010-11-12 DK DK13189092.3T patent/DK2719708T3/da active
- 2010-11-12 CN CN201610373755.5A patent/CN105999263B/zh active Active
- 2010-11-12 JP JP2012538994A patent/JP5931736B2/ja active Active
- 2010-11-12 PL PL13189092T patent/PL2719708T3/pl unknown
- 2010-11-12 HU HUE13189092A patent/HUE035605T2/en unknown
- 2010-11-12 ES ES15154165.3T patent/ES2647466T3/es active Active
- 2010-11-12 ES ES17197711T patent/ES2781299T3/es active Active
- 2010-11-12 ES ES13189092.3T patent/ES2655737T3/es active Active
- 2010-11-12 MX MX2016002120A patent/MX357972B/es unknown
- 2010-11-12 CA CA2780935A patent/CA2780935C/en active Active
- 2010-11-12 DK DK17197711.9T patent/DK3351558T3/da active
- 2010-11-12 RS RS20200651A patent/RS60390B1/sr unknown
- 2010-11-12 EP EP13189092.3A patent/EP2719708B1/en active Active
- 2010-11-12 EP EP15154165.3A patent/EP2896632B1/en active Active
- 2010-11-12 EP EP10785251A patent/EP2499162A2/en not_active Withdrawn
- 2010-11-12 NO NO13189092A patent/NO2719708T3/no unknown
- 2010-11-12 MX MX2016008205A patent/MX358013B/es unknown
- 2010-11-12 TW TW099139038A patent/TWI630916B/zh active
- 2010-11-12 PT PT131890923T patent/PT2719708T/pt unknown
- 2010-11-12 SI SI201031627T patent/SI2719708T1/sl unknown
- 2010-11-12 PL PL17197711T patent/PL3351558T3/pl unknown
- 2010-11-12 WO PCT/US2010/056430 patent/WO2011060206A2/en active Application Filing
- 2010-11-12 BR BR112012012160-0A patent/BR112012012160B1/pt active IP Right Grant
- 2010-11-12 EP EP17197711.9A patent/EP3351558B1/en active Active
- 2010-11-12 US US12/944,764 patent/US9101760B2/en active Active
- 2010-11-12 SI SI201032011T patent/SI3351558T1/sl unknown
- 2010-11-12 MX MX2012005589A patent/MX349513B/es active IP Right Grant
- 2010-11-12 AU AU2010319483A patent/AU2010319483B2/en active Active
- 2010-11-12 LT LTEP13189092.3T patent/LT2719708T/lt unknown
- 2010-11-12 RS RS20180048A patent/RS56741B1/sr unknown
- 2010-11-12 EP EP20151640.8A patent/EP3670539A1/en active Pending
- 2010-11-12 KR KR1020127015255A patent/KR101806323B1/ko active IP Right Grant
- 2010-11-12 PT PT171977119T patent/PT3351558T/pt unknown
- 2010-11-12 HU HUE17197711A patent/HUE049880T2/hu unknown
- 2010-11-15 AR ARP100104211 patent/AR080564A1/es unknown
- 2010-11-15 UY UY33034A patent/UY33034A/es not_active Application Discontinuation
-
2013
- 2013-04-25 US US13/870,796 patent/US9803025B2/en active Active
-
2015
- 2015-08-20 HK HK15108089.8A patent/HK1207651A1/xx unknown
-
2016
- 2016-01-05 JP JP2016000552A patent/JP6235620B2/ja active Active
- 2016-01-18 US US15/000,005 patent/US9988462B2/en active Active
-
2017
- 2017-10-26 JP JP2017206911A patent/JP2018076300A/ja active Pending
- 2017-10-27 US US15/796,361 patent/US20180134805A1/en active Pending
- 2017-12-13 CY CY20171101305T patent/CY1119751T1/el unknown
-
2018
- 2018-01-19 HR HRP20180104TT patent/HRP20180104T1/hr unknown
-
2019
- 2019-09-20 JP JP2019172295A patent/JP7317650B2/ja active Active
-
2020
- 2020-06-05 CY CY20201100505T patent/CY1123030T1/el unknown
- 2020-06-08 HR HRP20200921TT patent/HRP20200921T1/hr unknown
-
2021
- 2021-09-17 JP JP2021152652A patent/JP2022000445A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2719708T1 (sl) | Material in postopki za zdravljenje ali preprečevanje bolezni, povezanih s HER-3 | |
JP2013510868A5 (sl) | ||
JP2020011980A5 (sl) | ||
EP2844675B1 (en) | Humanized pan-her antibody compositions | |
JP2022058802A5 (sl) | ||
JP2008528486A5 (sl) | ||
KR20140023921A (ko) | ErbB 경로 저해제들에 대한 저항성을 극복하는 방법 | |
HRP20150443T1 (hr) | Djelotvorne tvari koje se vežu za notch i njihovi antagonisti te postupci njihove uporabe | |
RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
JP2008531576A5 (sl) | ||
JP2020514310A5 (sl) | ||
JP2008503476A5 (sl) | ||
SI2842573T1 (sl) | Monoklonska protitelesa proti receptorju 2 fibroblastnega rastnega faktorja | |
WO2016090024A4 (en) | Combination therapy for treatment of cancer | |
JP2018512402A5 (sl) | ||
HRP20240213T1 (hr) | Bispecifična antitijela protiv ceacam5 i cd47 | |
RU2011146339A (ru) | Комбинированная терапия с использованием агента (ов) против igfr и специфических ингибиторов igf-1r | |
CN109152838A (zh) | 用于治疗癌症的派姆单抗和玻玛西尼的组合 | |
US20150110788A1 (en) | Bispecific antibodies with an fgf2 binding domain | |
JP6368811B2 (ja) | 放射線感受性を調節するためのher3阻害剤 | |
KR20210025064A (ko) | 항-her1, her2 또는 her4 항체와 포지오티닙의 조합물 및 이의 사용 방법 | |
JP6989645B2 (ja) | ErbB3に特異的に結合する抗体、及びその用途 | |
CN111655725A (zh) | 用于治疗癌症的组合产品 | |
KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 pd-1 항체 및 아파티닙의 조합 치료의 용도 | |
RU2021105964A (ru) | Применение антитела к tim-3 при получении лекарственных средств для лечения опухолей |